Boston Scientific Corp (XTER:BSX)
€ 87 1.5 (1.75%) Market Cap: 126.63 Bil Enterprise Value: 134.92 Bil PE Ratio: 75.00 PB Ratio: 6.46 GF Score: 79/100

Boston Scientific Corp at UBS Global Healthcare Conference Transcript

May 21, 2019 / 12:00PM GMT
Matthew Charles Taylor
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

Okay. Good morning, everyone. Thanks for joining us for day 2 of UBS Healthcare Conference. I am Matt Taylor, the U.S. medical supplies devices analyst. And this morning, we are going to start with guests from Boston Scientific. So we've got Susie Lisa joining us from Investor Relations. Then also, Art Butcher, the SVP and President of the Endoscopy business, who has held that position since July of 2016, where he is responsible for bringing to market less invasive devices for treating GI and pulmonary tract infections. And then, also with him, we have Brian Dunkin, the VP of Medical Affairs for Endoscopy. And he has been in that role leading the development and execution of patient-centric medical affair strategy to support the creation and commercialization of Boston's innovative portfolio.

Questions & Answers

Matthew Charles Taylor
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot